Qi Yang
Guangzhou International Bio Island
Guangzhou, China
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.
Journal: Journal of virology
Published: December 09, 2025
Discovery of Tricyclic Derivative as Novel and Potent Respiratory Syncytial Virus Fusion Glycoprotein Inhibitor with an Improved Pharmacokinetic Profile.
Journal: Journal of medicinal chemistry
Published: September 11, 2025
Cholesterol-rich lipid rafts mediate endocytosis as a common pathway for respiratory syncytial virus entry into different host cells.
Journal: Microbiology spectrum
Published: July 31, 2025
MMP-9 regulates disulphide isomerase activity of TGM2 to enhance fusion glycoprotein-mediated syncytium formation of respiratory syncytial virus.
Journal: Protein & cell
Published: May 20, 2025
Construction of Minigenome Replicon of Nipah Virus and Investigation of Biological Activity.
Journal: Viruses
Published: April 03, 2025
Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies.
Journal: Virologica Sinica
Published: September 30, 2024
Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein.
Journal: Signal transduction and targeted therapy
Published: December 07, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026